Diagnostics of lung cancer by fragmentated blood circulating cell-free DNA based on machine learning methods
Thus, the CM has a good diagnostic value and does not require clinical or other data on tumor-associated biomarkers. The current method for LC detection has some advantages for future clinical implementation as a decision-making support system due to the performance of the CM requires data exclusively from NGS-analysis of blood plasma cfDNA fragmentation; the accuracy of the CM does not depend on any additional clinical data; the CM is highly interpretable and traceable; CM has appropriate modular architecture.
Authors
- Ivan O. Meshkov (ORCID: https://orcid.org/0000-0002-7358-6108)
- Larisa P. Safonova (ORCID: https://orcid.org/0000-0001-6607-7359)
- S. M. Yudin (ORCID: https://orcid.org/0000-0002-7942-8004)
- Anton А. Keskinov (ORCID: https://orcid.org/0000-0001-7378-983X)
- В. В. Макаров (ORCID: https://orcid.org/0000-0001-9495-0266)
- V. S. Yudin (ORCID: https://orcid.org/0000-0002-9199-6258)
- П.В. Ершов (ORCID: https://orcid.org/0000-0002-3386-6201)
- Ekaterina A. Snigir (ORCID: https://orcid.org/0000-0003-1245-7764)
- А. А. Ивашечкин (ORCID: https://orcid.org/0000-0002-0148-1112)
- Antonida V. Makhotenko
- А. С. Макарова (ORCID: https://orcid.org/0000-0002-9711-9256)
- E. D. Maralova
- V. V. Maksyutina (ORCID: https://orcid.org/0009-0003-8136-2379)
- Veronika Skvortsova
- Vasilisa A. Astafieva
- Boris D. Ignatiev
- Alexander P. Koturgin
- Julia A. Remizova
Institutions
- State Research Institute of Highly Pure Biopreparations (RU)
- Federal Medical-Biological Agency (RU)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-01-29
- DOI
- https://doi.org/10.3389/fmed.2025.1435428
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.87